TY - JOUR
T1 - Cardiotoxicities of Novel Therapies in Hematologic Malignancies
T2 - Chimeric Antigen Receptor T-Cell Therapy and Bispecific T-Cell Engager Therapy
AU - Marar, Rosalyn I.
AU - Abbasi, Muhannad Aboud
AU - Prathivadhi-Bhayankaram, Sruti
AU - Daryanani, Andres
AU - Villarraga, Hector
AU - Anavekar, Nandan
AU - Bhatt, Vijaya Raj
AU - Paludo, Jonas
N1 - Publisher Copyright:
© American Society of Clinical Oncology.
PY - 2023/6/1
Y1 - 2023/6/1
N2 - The field of malignant hematology is transforming with novel immunotherapeutic approaches. Unfortunately, quality of life, treatment efficacy, and life expectancy are negatively affected by cardiotoxic side effects of treatment. To date, the exact mechanism and incidence of cardiotoxicity associated with these therapies is unclear. These events are believed to be triggered or occur concurrently with cytokine release syndrome. Furthermore, there are no formal guidelines to provide evaluation, treatment, and surveillance. We aim to synthesize available literature with updates on the cardiotoxic effects of novel therapies used in malignant hematologic disorders, with a focus on chimeric antigen receptor T-cell therapy and bispecific T-cell engager therapy, along with a proposed algorithm that may guide pretreatment evaluation, monitoring during treatment, and post-treatment surveillance.
AB - The field of malignant hematology is transforming with novel immunotherapeutic approaches. Unfortunately, quality of life, treatment efficacy, and life expectancy are negatively affected by cardiotoxic side effects of treatment. To date, the exact mechanism and incidence of cardiotoxicity associated with these therapies is unclear. These events are believed to be triggered or occur concurrently with cytokine release syndrome. Furthermore, there are no formal guidelines to provide evaluation, treatment, and surveillance. We aim to synthesize available literature with updates on the cardiotoxic effects of novel therapies used in malignant hematologic disorders, with a focus on chimeric antigen receptor T-cell therapy and bispecific T-cell engager therapy, along with a proposed algorithm that may guide pretreatment evaluation, monitoring during treatment, and post-treatment surveillance.
UR - http://www.scopus.com/inward/record.url?scp=85163257526&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85163257526&partnerID=8YFLogxK
U2 - 10.1200/OP.22.00713
DO - 10.1200/OP.22.00713
M3 - Review article
C2 - 36930845
AN - SCOPUS:85163257526
SN - 2688-1527
VL - 19
SP - 331
EP - 342
JO - JCO Oncology Practice
JF - JCO Oncology Practice
IS - 6
ER -